Breaking News, Collaborations & Alliances

Amicus, Biogen in Parkinson’s Pact

Biogen to fund discovery, development, commercialization

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amicus Therapeutics and Biogen Idec have entered a collaboration to discover, develop and commercialize novel small molecules for the treatment of Parkinson’s disease. The collaboration will build upon preclinical studies at Amicus and independent published research that suggest increasing activity of the lysosomal enzyme glucocerobrosidase (GCase) in the brain may correct alpha-synuclein pathology and other deficits associated with Parkinson’s disease.   Amicus and BI will collabora...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters